武田Entyvio(vedolizumab) IV期VERDICT试验达标：疾病清除策略使溃疡性结肠炎并发症风险降低67%，但为已上市重磅药的上市后数据、无标签或收入增量

Takeda Pharmaceutical Company Limited (TAK) announced results from the Phase 4 VERDICT trial showing that treating adults with moderate to severe ulcerative colitis (UC) with ENTYVIO (vedolizumab) to achieve disease clearance significantly prolonged the time to first disease-related complication compared with targeting symptomatic remission alone.
The trial met its primary endpoint, with disease clearance associated with a 67% lower risk of UC-related complications (hazard ratio 0.33; 95% CI, 0.17-0.67; p=0.0014) over up to 80 weeks following treatment target achievement.
VERDICT evaluated 672 adults with moderate to severe UC randomized to three treatment targets: corticosteroid-free symptomatic remission; symptomatic plus endoscopic remission; or disease clearance, defined as symptomatic, endoscopic and histologic remission.
Treatment targets were assessed at Weeks 16, 32 and 48, with treatment adjustments based on ENTYVIO-based algorithms that could include increased dosing frequency.
Among patients who achieved their assigned targets, 52.1% in the disease-clearance group reached their target by Week 48, compared with 74.1% in the symptomatic-remission group.
More than half of patients who met their assigned treatment target achieved disease clearance by Week 16, according to the company.
Safety findings through 96 weeks were generally consistent with previously reported ENTYVIO data, with no new safety signals identified. Adverse event rates were similar across treatment groups and were not affected by treatment escalation or more frequent dosing.
Additional exploratory analyses identified molecular changes associated with disease clearance, including pathways related to inflammation, intestinal tissue repair and mucosal homeostasis.
The results were presented at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal.
ENTYVIO is a gut-focused biologic therapy approved for adults with moderately to severely active ulcerative colitis and Crohn's disease in multiple markets.
TAK is currently down 0.05% at $19.66.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.